Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMGN151 + carboplatin
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IMGN151 + carboplatin is a combination therapy under clinical investigation for gynecologic cancers. IMGN151 is a next-generation antibody-drug conjugate (ADC) designed to target folate receptor alpha (FRα) on tumor cells, using a biparatopic antibody that binds two non-overlapping epitopes on FRα and is conjugated to the potent maytansinoid derivative DM21 via a cleavable peptide linker. The combination with carboplatin, a platinum-based chemotherapy agent, is intended to maximize anti-tumor efficacy. This regimen is being evaluated for safety and efficacy in Phase 1 and 2 clinical trials, particularly in ovarian, endometrial, peritoneal, and fallopian tube cancers. IMGN151 is being developed by AbbVie following ImmunoGen’s pipeline; carboplatin is a well-established chemotherapy drug used in a variety of cancers[1][2][3][4].
- Other names
- opugotamig olatansine + carboplatin
02
Targets
FOLR1 (FRα)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on IMGN151 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMGN151 + carboplatin.